Replies to post #362834 on Innovation Pharmaceuticals Inc (IPIX)

[loanranger]

"Cover up! Cover up! They have all the relevant trial data and will not release it and play around with this silliness."

But they don't.
And there's a reason apart from the "blindness" of the trial:
The Company announced on June 3 that the trial had achieved full patient enrollment. So the last patient enrolled will only be able to be evaluated for the purpose of whether they met the Primary Outcome Measure on the 4th of July, give or take a day or two.

Isn't that true? Please answer.

I believe it to be true. Which would mean that your "Cover up!" assertion should be given a rest until at least around the second week of July.


Stuff could have happened before today that might weigh heavily on the Outcome but I don't see how they could "have all the relevant trial data". How could they know the "Time to sustained recovery through Day 29" when for some patients Day 29 has yet to occur?

[MackG]

"This is pathetic and embarrassing." This admission about your post is at least honest. I see that loanranger has set you straight.

[Lemoncat]

Cover up! Cover up! They have all the relevant trial data and will not release it and play around with this silliness.

Per the June 3 PR:

http://www.ipharminc.com/press-release/2021/6/3/innovation-pharma-completes-enrollment-in-phase-2-clinical-trial-for-covid-19

Complete trial enrollment comprised 120 dosed patients recruited across multiple sites. Final data collection for the last patient enrolled in the study is expected to occur in early August (Study Day 60), which will then be followed by the process of unblinding study data and the reporting of topline study results.

So you're claiming the company has unblinded the data, it was bad, and they then proceeded to lie about it in a PR? That sounds pretty far fetched at best.

It's more likely the 60 day followup has not been completed for all patients and the trial results are still blinded. You know, per the trial protocol and as explained in the PR.

Go IPIX!